Cyxone AB (publ) (CYXO.ST)
SEK 0.02
(0.0%)
SEK 0.02
(0.0%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -20.41 Million SEK | 50.67% |
| 2022 | -40.19 Million SEK | 7.03% |
| 2021 | -43.23 Million SEK | 8.41% |
| 2020 | -47.2 Million SEK | -41.45% |
| 2019 | -33.37 Million SEK | -120.67% |
| 2018 | -30.82 Million SEK | -71.82% |
| 2017 | -8.8 Million SEK | -293287.4% |
| 2016 | -3000.00 SEK | 98.15% |
| 2015 | 162 Thousand SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -3.44 Million SEK | -2.53% |
| 2024 Q1 | -3.99 Million SEK | 37.12% |
| 2023 Q2 | -5.26 Million SEK | 1.28% |
| 2023 Q1 | -5.33 Million SEK | -287.07% |
| 2023 FY | - SEK | 52.15% |
| 2023 Q4 | -5.26 Million SEK | -15.73% |
| 2023 Q3 | -4.55 Million SEK | 13.51% |
| 2022 FY | - SEK | 7.03% |
| 2022 Q3 | -10.64 Million SEK | 12.31% |
| 2022 Q4 | -1.37 Million SEK | 87.07% |
| 2022 Q2 | -12.14 Million SEK | 25.19% |
| 2022 Q1 | -16.23 Million SEK | -19.89% |
| 2021 Q1 | -8.16 Million SEK | 29.46% |
| 2021 Q2 | -11 Million SEK | -34.86% |
| 2021 Q3 | -10.52 Million SEK | 4.4% |
| 2021 FY | - SEK | 8.41% |
| 2021 Q4 | -13.53 Million SEK | -28.62% |
| 2020 Q4 | -11.57 Million SEK | 4.83% |
| 2020 Q1 | -9.64 Million SEK | 48.81% |
| 2020 FY | - SEK | -41.45% |
| 2020 Q2 | -13.73 Million SEK | -42.42% |
| 2020 Q3 | -12.15 Million SEK | 11.49% |
| 2019 Q4 | -18.84 Million SEK | -235.57% |
| 2019 FY | - SEK | -120.67% |
| 2019 Q3 | -5.61 Million SEK | -31.81% |
| 2019 Q2 | -4.26 Million SEK | 9.05% |
| 2019 Q1 | -4.68 Million SEK | -7.78% |
| 2018 Q1 | -2.69 Million SEK | 16.66% |
| 2018 FY | - SEK | -71.82% |
| 2018 Q2 | -3.75 Million SEK | -38.94% |
| 2018 Q3 | -4.27 Million SEK | -13.95% |
| 2018 Q4 | -4.34 Million SEK | -1.7% |
| 2017 Q1 | -1.45 Million SEK | -48266.67% |
| 2017 Q2 | -2.58 Million SEK | -77.81% |
| 2017 FY | - SEK | -293287.4% |
| 2017 Q3 | -1.5 Million SEK | 41.55% |
| 2017 Q4 | -3.23 Million SEK | -114.76% |
| 2016 Q4 | -3000.00 SEK | 99.76% |
| 2016 Q1 | -307 Thousand SEK | 0.0% |
| 2016 FY | - SEK | 98.15% |
| 2016 Q2 | -1.15 Million SEK | -276.87% |
| 2016 Q3 | -1.23 Million SEK | -6.66% |
| 2015 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 94.45% |
| Camurus AB (publ) | 562.54 Million SEK | 103.629% |
| Mendus AB (publ) | -97.84 Million SEK | 79.137% |
| Lipum AB (publ) | -37.11 Million SEK | 45.004% |
| NextCell Pharma AB | -40.98 Million SEK | 50.192% |
| Simris Alg AB (publ) | -22.36 Million SEK | 8.715% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -19.488% |
| Active Biotech AB (publ) | -43.88 Million SEK | 53.485% |
| Amniotics AB (publ) | -27.14 Million SEK | 24.791% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -43.589% |
| BioArctic AB (publ) | 275.38 Million SEK | 107.413% |
| Cantargia AB (publ) | -284.31 Million SEK | 92.82% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -4.265% |
| CombiGene AB (publ) | -35.33 Million SEK | 42.229% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | 85.507% |
| Genovis AB (publ.) | 64.57 Million SEK | 131.614% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | 82.234% |
| Isofol Medical AB (publ) | -37.02 Million SEK | 44.863% |
| Intervacc AB (publ) | -68.98 Million SEK | 70.406% |
| Kancera AB (publ) | -61.88 Million SEK | 67.015% |
| Karolinska Development AB (publ) | -26.78 Million SEK | 23.78% |
| LIDDS AB (publ) | -39.67 Million SEK | 48.54% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -68.655% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 165.004% |
| OncoZenge AB (publ) | 7.26 Million SEK | 380.952% |
| Saniona AB (publ) | -69.69 Million SEK | 70.71% |
| Vicore Pharma Holding AB (publ) | -317.46 Million SEK | 93.57% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | 92.762% |
| Xintela AB (publ) | -53.47 Million SEK | 61.822% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | 87.979% |
| Ziccum AB (publ) | -20.34 Million SEK | -0.354% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 1020800.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | 91.409% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -881.442% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -51.992% |
| Corline Biomedical AB | -1.69 Million SEK | -1107.215% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | 88.222% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | 62.752% |
| Aptahem AB (publ) | -10 Million SEK | -103.952% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 276.76% |
| Fluicell AB (publ) | -25.91 Million SEK | 21.224% |
| Biovica International AB (publ) | -119.5 Million SEK | 82.918% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | 51.653% |
| AcouSort AB (publ) | -16.7 Million SEK | -22.218% |
| Abliva AB (publ) | -93.6 Million SEK | 78.192% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 93.603% |
| 2cureX AB (publ) | -35.13 Million SEK | 41.9% |
| I-Tech AB | 30.34 Million SEK | 167.273% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 97.143% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | 80.075% |
| Biosergen AB | 228 Thousand SEK | 9053.509% |
| Nanologica AB (publ) | -62.11 Million SEK | 67.137% |
| SynAct Pharma AB | -222.7 Million SEK | 90.833% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | 53.458% |
| BioInvent International AB (publ) | -312.7 Million SEK | 93.472% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 6697.654% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 48705.919% |
| Oncopeptides AB (publ) | -231.62 Million SEK | 91.187% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -131.649% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | 81.195% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -77.993% |